LIR 生命科学开始第2阶段,以改进无针肥胖治疗的peptide交付。 LIR Life Sciences begins Phase 2 to improve peptide delivery for needle-free obesity treatments.

LIR生命科学已启动与Neuland实验室合作的肽设计项目第二阶段，旨在优化其经皮递送平台的细胞穿透肽。 LIR Life Sciences has started Phase 2 of a peptide design program with Neuland Laboratories to optimize cell-penetrating peptides for its transdermal delivery platform. 这项工作的重点是提高交付效率、制造业的可缩放性,以及利用基于蛋白胺的序列和结构-活动关系分析来灵活制定方案。 The effort focuses on improving delivery efficiency, manufacturing scalability, and formulation flexibility using protamine-based sequences and structure-activity relationship analysis. 目标是为无针、GLP-1-模拟治疗肥胖症开发先进的peptide候选药物,目的是增加获得和坚持治疗的机会。 The goal is to develop advanced peptide candidates for needle-free, GLP-1-mimicking treatments for obesity, aiming to enhance access and adherence. 成果将指导未来的合成和测试,支持LIR的更广泛使命,即创造负担得起、可扩展的疗法。 Results will guide future synthesis and testing, supporting LIR’s broader mission to create affordable, scalable therapies.